RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dumping 20M shares and keeping 10M warrants @$3.18 Jmf the preaching scientist is saying the successful clinical results are not a slam dunk thus this is why the company could not issue stock at a higher price!!! What a dumb statement
ALL other Public Companies involved im Nash clinical trials are valued at multiplles that of TH....
If TH data is that weak then why is TH involved?
scarlet1967 wrote: We can speculate all day re the timing, size and price tag for the deal, everyone is entitled to their opinion but the fact that their IR has not been successful is real.
As per a reliable source Leah was approached by cancer and NASH analysts more than a year ago so after more than a year she hasn't obviously been successful to bring them on board, so either she was lying or despite having two upcoming promising trials and multiple encouraging news she miserably failed to convince even one of those analysts, not a single one?
Why the company's website is less appealing than a fish and chips shop's website?
Why the investors presentation is taken down for days before a replacement is ready?
Why sending email notification prematurely?
Why not responding to emails?
Why not correcting false analysts reports by having interactive ongoing dialogue?
Why market doesn't ascribe $$ to their science?
Why other companies with less promising prospects are valued multiples of THTX?
There is a reason to have an IR department and the reason is to deal with all these questions now can someone tells me have they done anything to deal with those issues in case I have been a bit slow and missed...